

Donatella Aldinucci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4573056/donatella-aldinucci-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

4,168
citations

34
h-index

63
g-index

88
ext. papers

4,681
ext. citations

5
avg, IF

5.35
L-index

#	Paper	IF	Citations
84	Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma. <i>Cancers</i> , 2022 , 14, 2427	6.6	
83	In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
82	Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma. <i>Cancer Letters</i> , 2021 , 500, 182-193	9.9	11
81	Analogues of a Natural Peptaibol Exert Anticancer Activity in Both Cisplatin- and Doxorubicin-Resistant Cells and in Multicellular Tumor Spheroids. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
80	In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases 3D tumor-stroma heterospheroid viability. <i>Haematologica</i> , 2021 ,	6.6	2
79	The CCL5/CCR5 Axis in Cancer Progression. <i>Cancers</i> , 2020 , 12,	6.6	61
78	Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance. <i>Pharmaceutics</i> , 2020 , 12,	6.4	9
77	Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	17
76	Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives. <i>Cancers</i> , 2019 , 11,	6.6	28
75	CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. <i>Haematologica</i> , 2019 , 104, 564-575	6.6	37
74	Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media. <i>Stem Cell Research and Therapy</i> , 2018 , 9, 130	8.3	23
73	Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	66
72	New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. <i>Oncotarget</i> , 2017 , 8, 490-505	3.3	52
71	Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. <i>Oncotarget</i> , 2017 , 8, 42926-42938	3.3	16
70	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractionated cisplatin and metronomic etoposide and bevacizumab (mPEBv). <i>Oncotarget</i> , 2017 , 8, 75904-75913	3.3	18
69	Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl ₂ -activated platelet concentrates promoted expansion of mesenchymal stromal cells. <i>Vox Sanguinis</i> , 2016 , 111, 197-205	3.1	13
68	Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. <i>Cancer Letters</i> , 2016 , 380, 243-52	9.9	64

67	Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. <i>Blood</i> , 2015 , 126, 1394-7	2.2	40
66	Synthesis, characterization and anticancer activity of gold(III) complexes with (1R,2R)-[1,2-diaminocyclohexane. <i>Polyhedron</i> , 2015 , 102, 773-781	2.7	10
65	Preclinical activity of multiple-target gold(III)-dithiocarbamate peptidomimetics in prostate cancer cells and xenografts. <i>Future Medicinal Chemistry</i> , 2014 , 6, 1249-63	4.1	9
64	Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts. <i>Leukemia and Lymphoma</i> , 2014 , 55, 149-59	1.9	10
63	Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5496-506	12.9	35
62	The inflammatory chemokine CCL5 and cancer progression. <i>Mediators of Inflammation</i> , 2014 , 2014, 292376	4.6	260
61	The NF- κ B inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. <i>Cancer Letters</i> , 2014 , 349, 26-34	9.9	15
60	Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. <i>Gynecologic Oncology</i> , 2013 , 131, 744-52	4.9	33
59	Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. <i>Journal of Cellular Biochemistry</i> , 2013 , 114, 1135-44	4.7	27
58	The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. <i>Leukemia and Lymphoma</i> , 2012 , 53, 195-201	1.9	41
57	Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 2212-26	8.3	54
56	Rational design of gold(III)-dithiocarbamate peptidomimetics for the targeted anticancer chemotherapy. <i>Journal of Inorganic Biochemistry</i> , 2012 , 117, 248-60	4.2	32
55	t-Butylsarcosinedithiocarbamate gold(III)-based anticancer agents: Design, in vitro biological evaluation and interaction with model biomolecules. <i>Inorganica Chimica Acta</i> , 2012 , 393, 304-317	2.7	17
54	Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012 , 120, 2763-2763	2.2	
53	IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. <i>British Journal of Haematology</i> , 2011 , 152, 182-90	4.5	27
52	Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2011 , 226, 2131-8	7	70
51	Antitumor activity of gold(III)-dithiocarbamate derivatives on prostate cancer cells and xenografts. <i>International Journal of Cancer</i> , 2011 , 128, 206-15	7.5	103
50	IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2010 , 148, 115-8	4.5	16

49	Latest insights into the anticancer activity of gold(III)-dithiocarbamate complexes. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010 , 10, 283-92	2.2	62
48	Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. <i>Blood</i> , 2010 , 115, 746-7; author reply 748	2.2	7
47	The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. <i>Journal of Pathology</i> , 2010 , 221, 248-63	9.4	193
46	Groundbreaking gold(III) anticancer agents. <i>Drug Discovery Today</i> , 2009 , 14, 1075-1076	8.8	26
45	Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2009 , 125, 1092-101	7.5	80
44	Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. <i>International Journal of Cancer</i> , 2008 , 122, 769-76	7.5	113
43	The role of the EGFR signaling in tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2008 , 214, 559-67	7	280
42	Antiproliferative and apoptotic effects of two new Pd(II) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. <i>Oncology Research</i> , 2008 , 17, 103-13	4.8	3
41	Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. <i>Anti-Cancer Drugs</i> , 2007 , 18, 323-32	2.4	38
40	Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 1588-95	8.3	150
39	The role of interleukin-3 in classical Hodgkin's disease. <i>Leukemia and Lymphoma</i> , 2005 , 46, 303-11	1.9	26
38	Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. <i>Endocrine-Related Cancer</i> , 2005 , 12, 471-82	5.7	79
37	CD26 expression correlates with a reduced sensitivity to 2-Deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. <i>Clinical Cancer Research</i> , 2004 , 10, 508-20	12.9	22
36	Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1731-9	1.9	48
35	The role of interleukin-3 and stem cell factor in classical Hodgkin disease. <i>Blood</i> , 2003 , 101, 376-7	2.2	5
34	Interleukin-3 receptors in Hodgkin's disease. <i>American Journal of Pathology</i> , 2003 , 162, 355-6; author reply 356-7	5.8	3
33	CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. <i>Experimental Hematology</i> , 2002 , 30, 1283-92	3.1	27
32	Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. <i>British Journal of Haematology</i> , 2002 , 117, 59-69	4.5	9

31	Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. <i>British Journal of Haematology</i> , 2002 , 117, 366-72	4.5	84
30	Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. <i>British Journal of Haematology</i> , 2002 , 118, 1055-64	4.5	21
29	A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster. <i>Journal of Pathology</i> , 2002 , 197, 256-63	9.4	12
28	Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. <i>American Journal of Pathology</i> , 2002 , 160, 585-96	5.8	46
27	CD30L up-regulates CD30 and IL-4 expression by T cells. <i>FEBS Letters</i> , 2001 , 508, 418-22	3.8	18
26	In vitro and in vivo effects of 2Sdeoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. <i>British Journal of Haematology</i> , 2000 , 110, 188-96	4.5	24
25	CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation. <i>Leukemia and Lymphoma</i> , 1999 , 35, 21-35	1.9	9
24	Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. <i>British Journal of Haematology</i> , 1999 , 104, 152-62	4.5	17
23	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999 , 105, 225-240	4.5	17
22	Hodgkin's disease: a disorder of dysregulated cellular cross-talk. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1998 , 10, 309-20		18
21	Differential expression of the RET gene in human acute myeloid leukemia. <i>Annals of Hematology</i> , 1998 , 77, 207-10	3	12
20	Competitive reverse-transcriptase PCR: a useful alternative to northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. <i>Biochemical Journal</i> , 1997 , 325 (Pt 2), 565-7	3.8	14
19	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997 , 89, 3787-3794	2.2	51
18	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997 , 89, 2048-2059	2.2	101
17	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997 , 89, 3787-3794	2.2	1
16	. <i>Annals of Oncology</i> , 1997 , 8, 89-96	10.3	17
15	In Vitro Cellular Systems for Studying OC Function and Differentiation : Primary OC Cultures and the FLG 29.1 Model. <i>Methods in Molecular Medicine</i> , 1996 , 2, 277-306		1
14	Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. <i>Blood</i> , 1996 , 88, 3299-3305	2.2	107

13	Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.. <i>EMBO Journal</i> , 1996 , 15, 4949-4958	13	104
12	Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. <i>Blood</i> , 1995 , 85, 780-789	2.2	171
11	Differential expression of a novel proline-rich homeobox gene (Prh) in human hematolymphopoietic cells. <i>Blood</i> , 1995 , 85, 1237-1245	2.2	59
10	The expression of CD26 and CD40 ligand is mutually exclusive in human T- cell non-Hodgkin's lymphomas/leukemias. <i>Blood</i> , 1995 , 86, 4617-4626	2.2	69
9	Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3'Scyclic monophosphate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 8884-8	11.5	21
8	Interleukin 1 is an autocrine regulator of human endothelial cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 6487-91	11.5	155
7	Superoxide-driven NAD(P)H oxidation induced by EDTA-manganese complex and mercaptoethanol. <i>Chemico-Biological Interactions</i> , 1990 , 76, 3-18	5	39
6	Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia. <i>International Journal of Cancer</i> , 1990 , 46, 902-7	7.5	14
5	Biologic and clinical significance of cytokine production in B-cell malignancies. <i>European Journal of Haematology</i> , 1989 , 51, 35-42	3.8	6
4	Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 2369-73	11.5	104
3	A sensitive spectrophotometric method for the determination of superoxide dismutase activity in tissue extracts. <i>Analytical Biochemistry</i> , 1986 , 154, 536-41	3.1	422
2	Immunoaffinity purification of rat liver transketolase: evidence for multiple forms of the enzyme. <i>Archives of Biochemistry and Biophysics</i> , 1986 , 245, 212-9	4.1	8
1	Preparative enzymic synthesis and isolation of d-threo-2-pentulose 5-phosphate (d-xylulose 5-phosphate). <i>Carbohydrate Research</i> , 1985 , 143, 288-293	2.9	26